Relative Risk of Death After HLA-Identical Sibling Bone Marrow Transplantations for Severe Aplastic Anemia Between 1986 and 1992
| Variable . | Adjusted for Patient-, Disease-, and Transplant-Related Variables . | |
|---|---|---|
| . | Relative Risk . | 95% CI . |
| Year of transplant | ||
| 1986-1987 | 1.004-150 | — |
| 1988-1992 (≤3 mo) | 0.564-151 | 0.37-0.84 |
| 1988-1992 (>3 mo) | 1.48 | 0.96-2.30 |
| Increasing age (per yr of age) | 1.024-151 | 1.01-1.03 |
| Neutrophils (<0.2 × 109/L v ≥0.2 × 109/L) | — | NS |
| >20 Transfusions (v ≤20 transfusions) | 2.06‡ | 1.50-2.83 |
| Prior treatment (v no prior treatment) | — | NS |
| Time to transplant >2 mo (v ≤2 mo) | — | NS |
| Donor-recipient sex-mismatch (v sex-match) | — | NS |
| Cell dose ≥3 × 108/kg (v <3 × 108/kg) | — | NS |
| Buffy coat cells (v no buffy coat cells) | — | NS |
| Conditioning regimen4-155 | — | NS |
| Intravenous immune globulins (v no intravenous immune globulins) | 0.59ρ | 0.42-0.79 |
| Systemic antibiotics (v no antibiotics) | — | NS |
| Cotrimoxazole (v no cotrimoxazole) | 0.664-151 | 0.50-0.89 |
| Acyclovir (v no acyclovir) | — | NS |
| Growth factor4-154 (v no growth factors) | — | NS |
| HEPA/LAF (v no HEPA/LAF) | — | NS |
| GVHD prophylaxis | ||
| MTX + CSA | 1.004-150 | — |
| CSA | 1.15 | 0.85-1.56 |
| MTX | 2.404-151 | 1.33-4.34 |
| T-cell depletion | 0.65 | 0.26-1.59 |
| Other4-167 | 5.82‡ | 2.65-12.77 |
| Variable . | Adjusted for Patient-, Disease-, and Transplant-Related Variables . | |
|---|---|---|
| . | Relative Risk . | 95% CI . |
| Year of transplant | ||
| 1986-1987 | 1.004-150 | — |
| 1988-1992 (≤3 mo) | 0.564-151 | 0.37-0.84 |
| 1988-1992 (>3 mo) | 1.48 | 0.96-2.30 |
| Increasing age (per yr of age) | 1.024-151 | 1.01-1.03 |
| Neutrophils (<0.2 × 109/L v ≥0.2 × 109/L) | — | NS |
| >20 Transfusions (v ≤20 transfusions) | 2.06‡ | 1.50-2.83 |
| Prior treatment (v no prior treatment) | — | NS |
| Time to transplant >2 mo (v ≤2 mo) | — | NS |
| Donor-recipient sex-mismatch (v sex-match) | — | NS |
| Cell dose ≥3 × 108/kg (v <3 × 108/kg) | — | NS |
| Buffy coat cells (v no buffy coat cells) | — | NS |
| Conditioning regimen4-155 | — | NS |
| Intravenous immune globulins (v no intravenous immune globulins) | 0.59ρ | 0.42-0.79 |
| Systemic antibiotics (v no antibiotics) | — | NS |
| Cotrimoxazole (v no cotrimoxazole) | 0.664-151 | 0.50-0.89 |
| Acyclovir (v no acyclovir) | — | NS |
| Growth factor4-154 (v no growth factors) | — | NS |
| HEPA/LAF (v no HEPA/LAF) | — | NS |
| GVHD prophylaxis | ||
| MTX + CSA | 1.004-150 | — |
| CSA | 1.15 | 0.85-1.56 |
| MTX | 2.404-151 | 1.33-4.34 |
| T-cell depletion | 0.65 | 0.26-1.59 |
| Other4-167 | 5.82‡ | 2.65-12.77 |
Abbreviation: NS, not significant.
Baseline.
P < .01.
P < .0001.
ρ P < .001.
Categories considered: cyclophosphamide alone, Cy + ATG, Cy + TBI, Cy + LFR, and other.
Granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor administered within 1 week of transplantation.
Other means corticosteroids, no GVHD prophylaxis.